The Top Line

Locking in on pharma’s consumerization trend

Fierce Pharma Week: A look at the biggest trends, campaigns and conversations

Inside the growing world of biopharma prediction markets

Clinical trials reach a new automation inflection point (Sponsored)

The future of RAS inhibitors

The recent approval of Revolution Medicines’ RAS inhibitor for advanced pancreatic cancer marks a significant milestone in oncology, validating the RAS pathway as a viable therapeutic target. Verastem Oncology CEO Dan Paterson and Chief Scientific Officer Jonathan Pachter emphasize that while this breakthrough offers a...

The people who stayed with the problem

MrBeast, Snapchat, AI and more: Pharma marketing’s pulse check

What did we learn from Big Pharma’s Q2 results?

Big Pharma maintained robust financial performance throughout the second quarter, with nine of the top 25 drug makers achieving double-digit revenue growth despite looming patent cliffs and shifting regulatory environments. Pharmaceutical companies are moving beyond general AI hype, integrating specific productivity to...

A genomics library for the AI era

Regeneron Genetics Center (RGC) leverages a massive, longitudinal genomic dataset to drive drug discovery and validate therapeutic targets. By sequencing over 3 million individuals—with a goal of reaching 20 million—the center prioritizes data diversity, particularly among non-European populations, to mitigate scientif...

How consumerization is reshaping pharma marketing (Sponsored)

The consumerization of healthcare, accelerated by GLP-1 medications, AI, and telemedicine, is fundamentally reshaping how patients interact with the medical system. Rachel Stoll and Kevin Nalty from Princeton 10 highlight that patients now frequently utilize digital wellness tools and AI to research symptoms before con...

Novo Nordisk’s CFO on the oral Wegovy rollout and beyond

Novo Nordisk’s second-quarter earnings exceeded market expectations, prompting a significant increase in full-year guidance driven by robust volume growth in the GLP-1 franchise. CFO Karsten Munk Knudsen highlights that the European rollout of the oral Wegovy pill, particularly in the UK, is experiencing rapid uptake v...

The next frontier in patient support: Connected data, AI and personalized engagement (Sponsored)

Patient services in life sciences are evolving from fragmented, reactive data silos into connected, AI-driven ecosystems designed to improve therapy adherence and patient outcomes. Despite an abundance of data from hubs and specialty pharmacies, poor integration currently hampers decision quality, contributing to signi...

Inside Noble’s connected approach to patient support (Sponsored)

The shift toward self-administered therapies necessitates that pharmaceutical companies integrate patient onboarding, device training, and ongoing engagement into a seamless, unified journey. Prioritizing the patient voice as a "North Star" allows organizations to identify specific pain points and avoid the pitfalls of...

Psychedelics, peptides and GLP-1s

GSK’s first lung cancer approval, a new IPO path and more

The biopharma industry is navigating a period of significant regulatory, clinical, and financial evolution. Legislative efforts in the U.S. House are pushing the FDA to modernize drug testing by incorporating computational models and organoids, potentially shifting the preclinical research landscape away from tradition...

Why modern clinical trials need a finance-first strategy (Sponsored)

5 emerging biotech hubs

Decision readiness is the next AI advantage (Sponsored)

A $10B deal, China trial scrutiny and highlights from ADA 2026

The deal before the deal